• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sponsors using partnerships to speed development

Sponsors using partnerships to speed development

October 11, 2011
CenterWatch Staff

Responding to strong and growing pressure to reduce development times and increase the output of new medicines, drug companies are engaging in innovative partnerships that are leading to, among other things, more molecular entities entering phase I trials and shorter study times, according to a panel of leaders from the drug research industry recently convened by the Tufts Center for the Study of Drug Development.

“Drug developers have gotten the message that they need to innovate ‘better, faster, and cheaper’—without sacrificing patient safety—and partnering is proving to be an effective strategy,” said Tufts CSDD director Kenneth I Kaitin. “By aligning with others, drug developers are hoping to accelerate the translation of scientific findings into new medicines.”

The emphasis on speeding drug development is driven, in part, by the pending expiration of a number of patents on more than a dozen blockbuster drugs, putting potentially more than $200 billion in sales at risk over the next several years.

According to Kaitin, one large pharmaceutical company, teaming with external partners, reported increasing the number of new molecular entities entering phase I trials from an average of five a year to 16. The company said it raised its phase II success rates from 14% to 41% during a recent five-year period.

The industry executives, who met as part of the Tufts CSDD executive forum roundtable, also reported:

  • A new entity, known as a technology scout organization, is helping large pharmaceutical companies identify enabling technologies and platforms that currently are not being commercialized.
  • “Umbrella agreements” with large universities enable developers to broaden and deepen relationships with individual researchers—to identify advances with potential to be developed into marketable products.
  • Trial sharing, in which two companies share the same phase I clinical trial, has enabled developers to quickly learn whether joint administration of their compounds can enhance therapeutic outcomes.

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

  • Inspection-360x240.png

    Pandemic Caused 34 Percent Drop in FDA Investigator Inspections in Fiscal 2020

  • ImproveEfficiency-360x240.png

    Firm Fees, Coordinated Workflows Among Ways Sites Can Improve Efficiency

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing